ALK-Abelló A/S (LON:0OIR)
London · Delayed Price · Currency is GBP · Price in DKK ALK-Abelló Company Description
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.
Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma.
The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food.
It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that provide support, guidance, and relief, as well as smoothing the path to allergy immunotherapy treatment.
In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis.
It has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX, a grass pollen allergy tablet; CEDARCURE, a tablet for the treatment of Japanese cedar pollen induced allergy; and MITICURE for the treatment of house dust mite-induced allergy.
ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
| Country | Denmark |
| Founded | 1923 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 2,753 |
| CEO | Peter Halling |
Contact Details
Address: Bøge Allé 6-8 Hørsholm, 2970 Denmark | |
| Phone | 45 45 74 75 76 |
| Website | alk.net |
Stock Details
| Ticker Symbol | 0OIR |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0061802139 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Peter Halling | President and Chief Executive Officer |
| Claus Steensen Solje | Executive Vice President, Chief Financial Officer and Member of Management Board |
| Søren Daniel Niegel | Executive Vice President of Commercial Operations and Member of Management Board |
| Dr. Henriette Mersebach | Executive Vice President Research and Development & Member of Management Board |
| Katja Barnkob Thalund | Senior Project Director, Global Clinical Development and Employee-elected Director |
| Lise Lund Maerkedahl | Project Director of Global Research and Employee-elected Director |
| Per Plotnikof | Vice President of Corporate Communications, Investor Relations and Strategic Planning and Head of IR |
| Jacob Glenting | Senior Vice President of Global Strategy and Corporate Development |
| Lika Thiesen | Executive Vice President of Global People and Organisation |
| Prof. Hendrik Kees Kam Nolte M.D., Ph.D. | Senior Vice President of Research and Development - North America and International Markets |